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Abstract: Our aim was to study changes in red blood cell (RBC) membrane band 3 profile, as a cumulative marker of 
RBC changes, in chronic kidney disease (CKD) patients under haemodialysis and recombinant human erythropoietin 
(rhEPO) therapy and its linkage with resistance to this therapy.  
We studied 63 CKD patients, 32 responders and 31 non-responders to rhEPO therapy, and 26 healthy individuals. We 
evaluated the band 3 profile [% of band 3 monomer, high molecular weight aggregates (HMWAg), and proteolytic frag-
ments (Pfrag)], membrane-bound haemoglobin (MBH), haematological data, total serum bilirubin, glutathione peroxidase 
(GPx) and superoxide dismutase activities, total antioxidant status (TAS) and plasma lipid peroxidation (TBA). Compared 
to controls, band 3 profile presented by CKD patients showed statistically significant lower HMWAg and Pfrag values 
and a significant higher value in band 3 monomer. GPx, TBA and TAS activities, and TBA/TAS ratio were also signifi-
cantly higher in CKD patients. Comparing responders to non-responders CKD patients, significantly lower value in Pfrag 
and a trend for a higher value in MBH were found in non-responders.  
Our data suggest that CKD patients present younger RBC population, which could be related to the rhEPO therapy. The 
adverse plasma environment associated to CKD patients under hemodialysis imposes changes in band 3 profile, particu-
larly in non-responders, suggesting that resistance to rhEPO therapy in CKD patients seems to be associated to an increase 
in RBC damage. 
Key-Words: Band 3 protein; Membrane bound haemoglobin; oxidative stress, RBC, Haemodialysis, Resitance to rhEPO 
therapy. 
INTRODUCTION 
 Haemodialysis increases longevity of patients with end-
stage renal disease by removing the metabolic end products 
and excess of water. Despite the technologic developments 
of haemodialysis procedures and of medical support in the 
last years, the morbidity and mortality of these patients re-
main high, about 10 to 20 times higher than that found in 
general population [1-3]. Anaemia is a frequent complication 
associated with chronic kidney disease (CKD), and is mainly 
due to insufficient erythropoietin renal production.  
 Until 18 years ago, the treatment of anaemia of CKD was 
blood transfusion; however, the management of this anaemia 
has been improved by the introduction of recombinant hu-
man EPO (rhEPO) therapy. This therapy allowed a signifi-
cant reduction in the associated adverse effects of anaemia 
and improved patient’s quality of life. There is, however, a  
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marked variability in the sensitivity to rhEPO, with up to 10-
fold variability in dose requirements to achieve correction of 
the anaemia [4-10].  
 Although oxygen is essential to human life, paradoxi-
cally, it can also cause great harm via oxidation/reduction 
reactions and formation of reactive oxygen species (ROS). 
Oxidative stress and its related biological effects have a 
pathologic relevance in many disease states, namely, in those 
having an associated inflammatory component [6-8]. There 
are increasing evidence that ROS are involved in the pro-
gression of renal damage and uraemic symptoms. The oxida-
tive stress appears to be multifactorial and is thought to be 
caused only in part by the impaired kidney function [6-8]. 
The several factors that have been implicated in the devel-
opment of oxidative stress in CKD patients undergoing 
haemodialysis include the haemodialysis procedure, urae-
mia, inflammation, disturbances in iron homeostasis, and 
reduction in the antioxidant defence systems. The later in-
cludes enzymatic systems involved in red blood cell (RBC) 
antioxidant defence, such as superoxide dismutase (SOD) 
and glutathione peroxidase (GPx). These enzymes are impor-
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tant to maintain higher levels of reduced glutathione, which 
is important in detoxifying the cell from ROS, and, therefore, 
in protecting the cell from their deleterious effects. Most of 
these factors are described also as independent factors of 
resistance to rhEPO therapy, particularly inflammation [11-
15]. 
 The RBC, presenting a limited biosynthesis capacity, 
suffers and accumulates physical and/or chemical changes, 
which become more pronounced with cell aging, and when-
ever an unusual physical or chemical stress develops [16]. 
RBCs that develop intracellular defects earlier during their 
life span are removed prematurely from circulation [16-20]. 
The removal of senescent or damaged RBCs seems to in-
volve the binding of a senescent neoantigen the RBC mem-
brane surface, marking the cell for death. This neoantigen is 
immunologically related to band 3, a RBC transmembrane 
protein [18]. The degradation of the RBC metabolism and/or 
of its antioxidant defences may lead to the development of 
oxidative stress within the cell, allowing oxidation of hae-
moglobin (Hb) and its linkage to the cytoplasmatic domain 
of band 3, promoting its aggregation. This aggregation con-
ditioned the binding of natural antiband 3 autoantibodies and 
complement activation, marking RBC for death.  
 An abnormal band 3 profile [high molecular weight ag-
gregates (HMWAg), band 3 monomer, and proteolytic frag-
ments (Pfrag)], has been associated to younger, damage 
and/or senescence RBCs. Older and damaged RBCs pre-
sented higher band 3 aggregation and lower fragmentation. 
The younger RBCs showed reduced aggregation and higher 
fragmentation [16-20]. 
 Our aim was to study RBC damage and oxidative stress 
status occurring in CKD patients under haemodialysis and 
rhEPO therapy. The study was performed in a healthy con-
trol group and in two groups of CKD patients (responders 
and non-responders). Some of the CKD patients were also 
evaluated before and immediately after haemodialysis to 
study the effect of the dialysis procedure per se. We per-
formed a basic RBC study, by evaluating RBC count, Hb 
concentration, haematocrit (Ht) and the haematimetric in-
dexes; the band 3 profile was evaluated as a cumulative 
marker of RBC damage; reticulocyte count, reticulocyte pro-
duction index (RPI) and bilirubin levels, as markers of RBC 
production/removal; SOD and GPx activities, as markers of 
RBC antioxidant capacity; membrane bound Hb (MBH), as a 
marker of oxidative Hb damage; plasma total antioxidant 
status (TAS) and lipidic peroxidation (TBA), as well as the 
ratio TBA/TAS were studied to evaluate the oxidative stress 
in the plasma RBC environment.  
MATERIAL AND METHODS  
Subjects  
 We studied 89 individuals including 63 CKD patients, 32 
responders and 31 non-responders to rhEPO therapy, and 26 
healthy controls. The rhEPO maintenance dose for re-
sponder’s patients was 90 ± 58 U/Kg/week and for non-
responders was 573 ± 194
 
U/Kg/week. The two groups of 
patients were matched for age, gender, weight, body mass 
index, mean time under haemodialysis, urea reduction ratio, 
urea Ktv and parathyroid hormone serum levels.  
 No analytical indicators of iron deficiency and/or vitamin 
B12 and folate deficiencies were found in CKD patients and 
controls (data not shown). 
 The causes of renal failure in patient’s population were as 
follows: diabetic nephropathy (n=19), chronic glomeru-
lonephritis (n=11), polycystic kidney disease (n=3), hyper-
tensive nephrosclerosis (n=3), obstructive nephropathy 
(n=3), pyelonephritis associated with neurogenic bladder 
(n=1), nephrolithiasis (n=1), chronic interstitial nephritis 
(n=1), Alport syndrome (n=1), renal vascular disease due to 
polyarteritis (n=1) and chronic renal failure of uncertain ae-
tiology (n=19).  
 Patients with autoimmune diseases, malignancies, hae-
matological disorders, inflammatory disorders and acute or 
chronic infections, were excluded. All subjects gave their 
informed consent to participate in this study. Classification 
of CKD patients as responders or non-responders was per-
formed in accordance with the European Best Practice 
Guidelines [21] that defines resistance to rhEPO as a failure 
to achieve target Hb levels (11-12 g/dL) with doses of epo-
etin more than 300 U/Kg /week or 1.5 mg/Kg /week of dar-
bopoietin-alfa.  
 Age and gender-matched individuals, with normal hae-
matological and biochemical values, without any history of 
renal or inflammatory diseases were used as controls. 
ASSAYS 
Blood Samples 
 Blood samples were collected from CKD patients before 
starting haemodialysis. In 20 of the CKD patients (10 re-
sponders and 10 non-responders to rhEPO therapy), blood 
samples were also collected immediately after the dialysis 
session.  
 Blood samples were collected with and without EDTA as 
anticoagulant, in order to obtain whole blood and serum. 
Whole blood was used for hematological procedures. To 
access GPx and SOD activities, whole blood and isolated 
and washed RBC aliquots, respectively, were made and 
stored at 70°C, until assayed. Plasma and serum aliquots 
were also made and stored at 70°C, until assayed. 
Haematological and Biochemical Studies 
 RBC count, Ht, Hb concentration, haematimetric indices 
[mean cell volume (MCV), mean cell Hb (MCH) and mean 
cell Hb concentration (MCHC)] and red cell distribution 
width (RDW) were measured by using an automatic blood 
cell counter (Sysmex K1000; Sysmex, Hamburg, Germany).  
 Reticulocyte count was performed by microscopic count-
ing on blood smears, after vital staining with New methylene 
blue (reticulocyte stain; Sigma, St Louis, MO, USA). The 
reticulocyte production index (RPI) was calculated as an 
appropriate way to measure the effective RBC production, 
by considering both changes in Ht (degree of anaemia) and 
in the premature reticulocyte release from the bone marrow 
[22].  
 Erythrocyte GPx and SOD activities were evaluated by 
using commercially available kits (RANSEL and RANSOD,  
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Randox, UK, respectively). Total antioxidant status (TAS) 
was evaluated in serum by a commercial colorimetric assay 
(TAS, Randox). Plasma lipidic peroxidation was estimated 
by TBA assay [23]. Moreover, the ratio TBA/TAS was 
evaluated.  
 Serum total bilirubin levels were evaluated in an auto-
analyser (Cobas Mira S, Roche), using a commercially 
available kit (Bilirubin total, ABX Diagnostics). Serum C-
reactive protein (CRP) was determined by immunoturbidi-
metry (CRP latex HS Roche kit, Roche Diagnostics). 
Preparation of Erythrocyte Membranes 
 Plasma and white blood cells were isolated from RBCs 
and discarded after centrifugation on a double density 
gradient (Histopaque 1.077 and 1.119, Sigma). RBCs were 
washed in saline, and immediately lysed, according to Dodge 
method [24]. The membranes were carefully washed in 
Dodge buffer (the first two washes used phenylmethylsulfo- 
nyl fluoride, a protease inhibitor, at a final concentration of 
0.1 μM). Protein concentration of the membrane suspensions 
was determined [25]. 
Membrane-Bound Hb (MBH) 
 MBH was measured spectrophotometrically at 415 nm, 
after protein dissociation with Triton X-100 (5% in Dodge 
buffer). The background was read at 700 nm to correct the 
absorbance at 415 nm; the obtained value and the protein 
concentration were used to estimate the percentage of MBH. 
Band 3 Profile 
 RBC membranes were treated with an equal volume of a 
solubilisation buffer containing 0.125 M Tris HCl pH 6.8, 
4% sodium dodecil sulphate (SDS), 20% glycerol, and 10% 
2-mercaptoethanol, heat-denatured and submitted to 
polyacrylamide gel electrophoresis (SDS-PAGE) (20 g 
protein/lane), using the discontinuous Laemmli system [26] 
(a 9% separating gel and a 4.5% stacking gel). Membrane 
proteins were electrophoretically transferred from gels to a 
nitrocellulose sheet with a porosity of 0.2 m (Sigma) [27]. 
Additional reactive sites on the nitrocellulose were blocked 
by incubation in 5% of low fat dry milk and 0.1% Triton-X 
100 in PBS (phosphate-buffered saline), pH 7.0, for 1 h at 
room temperature and under gentle rotation. Band 3 
immunoblot was performed [18]; monoclonal antibodies 
antihuman band 3, produced in mouse, recognizing an 
epitope located in the cytoplasmic pole of the band 3 
molecule [28] (Sigma), were added (dilution 1:3000) and 
incubated for 4 h; the washing of the nitrocellulose was 
followed by the addition and incubation with antimouse Ig 
peroxidase linked (Sigma) for 1 h (dilution 1:4000). The 
incubations were carried out at room temperature; the 
dilutions of the antibodies were prepared with PBS pH 7.0 
containing 0.1% Triton-X 100 and 5% of low fat dry milk. In 
the washes, the same buffer without dry milk was used. 
Hydrogen peroxide and -cloronaphtol were used to develop 
the immunoblot. The band 3 profile was quantified by 
densitometry (Bio1D++ version 99; Vilber Lourmat, 
France). We evaluated the percentage of HMWAg, of band 3 
monomer and of Pfrag. 
DATA ANALYSIS 
 Statistical analyses were carried out using the Statistical 
Package for Social Sciences (SPSS). Multiple comparisons 
between groups were performed by one-way ANOVA sup-
plemented with Tukey´s honestly significant difference 
(HSD) post hoc test. For data not normally distributed, dif-
ferences between the three groups were evaluated by the 
Kruskal-Wallis test; for single comparisons (two groups), the 
Mann-Whitney U test was used. To assess the influence of 
the haemodialysis procedure per se on the evaluated parame-
ters, paired t-test or Wilcoxon test were used. Significance 
was accepted at p less than 0.05. 
 Diabetic patients have been associated to an increased 
oxidative stress [29,30]. To exclude this possible confound-
ing factor we further analysed the results, by performing 
statistical analysis with and without exclusion of the 19 CKD 
patients with a diabetic nephropathy.  
RESULTS 
 The results were analysed in order to study the differ-
ences between healthy controls and CKD patients; to study 
the differences between responders and non-responders CKD 
patients (cross-sectional study), and to study changes im-
posed by the haemodialysis procedure. 
 We found that most of the CKD patients (all patients vs 
controls) presented anaemia with significantly lower RBC 
count (3.68 ± 0.54 x 10
12
/L vs 4.72 ± 0.59 10
12
/L, p<0.05), 
Hb [10.90 g/dL (10.30-12.30 g/dL) vs 13.90 g/dL (13.20-
15.00 g/dL), p<0.05)] and Ht [34.20 % (30.60-37.10 %) vs 
43.10% (40.10-46.70%), p<0.05)]; higher reticulocyte count 
(61.03 ± 31.36 x 10
9
/L vs 33.57 ± 22.78 10
9
/L, p<0.05), RPI 
[0.98 (0.58-1.40) vs 0.42 (0.19-0.66), p<0.05)] and RDW 
(15.92 ± 2.56% vs 12.79 ± 0.52 %, p<0.05) values were also 
observed. CKD patients showed (Fig. 1) statistically signifi-
cant lower HMWAg [15.23 % (13.38-19.40 %) vs 19.90 % 
(15.42-21.12%), p<0.05)] and Pfrag (22.70 ± 6.01% vs 26.29 
± 4.78 %, p<0.05) values, and higher Band 3 monomer val-
ues [61.84 % (56.87-64.41 %) vs 55.28 % (53.39-57.41%), 
p<0.05)]. The ratios HMWAg/band 3 monomer (0.27 ± 0.07 
vs 0.33 ± 0.07, p<0.05) and Pfrag/band 3 monomer (0.38 ± 
0.13 vs 0.48 ± 0.13, p<0.05) were also lower. GPx activity 
(45.82 ± 13.69 IU/g Hb vs 35.62 ± 8.83 IU/g Hb, p<0.05), 
TBA (1.49 ± 0.31 x10
-3
 mmol/L vs 0.84 ± 0.27 x10
-3
 mmol/L 
p<0.05), TAS (1.79 ± 0.24 mmol/L vs 1.41 ± 0.29 mmol/L, 
p<0.05) and CRP levels [5.76 mg/dL (1.90-14.01 mg/dL) vs 
1.75 mg/dL (0.76-4.70 mg/dL), p<0.05)], and TBA/TAS 
ratio (0.85 ± 0.18 vs 0.60 ± 0.28, p<0.05) were higher in 
CKD patients. Similar values for the activity of SOD and for 
MBH, between controls and patients, were observed.  
 In Table 1, we present the haematological data, for con-
trols and CKD patients. When comparing the haematological 
data between the two groups of CKD patients, we found that 
non-responders patients were all anaemic and showed sig-
nificantly lower values of Hb and Ht; their RBCs were more 
hypocromic, as reflected by the significantly lower values of 
MCH and MCHC; a significantly higher RDW was also ob-
served (Table 1). Statistically significant decreases in Pfrag 
and in the Pfrag/band 3 monomer ratio, and increase CRP 
were also found in non-responders CKD patients (Table 2). 
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 Analysing the results for the studied parameters, before 
and immediately after the dialysis procedure, in 20 of the 
studied CKD patients, we found a statistically significant rise 
in Hb [12.10 (10.95-12.80 g/dL) vs 13.20 (11.15-14.60 
g/dL), p<0.05] and significant decreases in MBH [75.00 
(49.00-109.50 x10
-4
%) vs 24.50 (13.00-64.50 x10
-4
%), 
p<0.05], in plasma TBA (1.52 ± 0.30 x10
-3
 mmol/L vs 1.36 ± 
0.26 x10
-3
 mmol/L, p<0.05) and in plasma TAS (1.58 ± 0.38 
mmol/L vs 1.26 ± 0.35 mmol/L, p<0.05) after haemodialysis. 
The other studied parameters remain unchanged after 
haemodialysis. No statistically significant differences were 
found between responders and non-responders patients, for 
the studied changes after the haemodialysis procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Examples of densitometer tracing of immunoblots for band 3 profile. A- Control; B- Responder patient; C- Non-responder patient. 
Table 1. Haematological Data for Controls and CKD Patients Under Haemodialysis and rhEPO Therapies 
 Controls  
(n=26) 
Responders  
(n=32) 
Non-Responders  
(n=31) 
Hb (g/dL) 13.90 (13.2-15.00) 11.70 (10.83-12.68) * 10.4 (9.00-11.30) * §  
Haematocrit (%) 43.10 (40.10-46.70) 35.15 (32.25-38.35) * 31.10 (27.70-35.20) * § 
RBC (x1012/L) 4.72 ± 0.59 3.76 ± 0.42 b) 3.58 ± 0.64 * 
MCV (fL) 92.00 (90.00-94.00) 95.80 (92.48-98.08) * 92.30 (85.40-100.30) 
MCH (pg) 29.83 ± 1.39 31.29 ± 1.53 b) 28.97 ± 3.73 § 
MCHC (g/dL) 32.48 ± 0.58 33.16 ± 1.77 30.85 ± 2.35 * § 
RDW (%) 12.79 ± 0.52 14.56 ± 1.23 * 17.32 ± 2.83 * § 
Reticulocytes (x109/L) 33.57 ± 22.78 55.12 ± 30.98 * 67.14 ± 31.06 * 
RPI 0.42 (0.19-0.66) 1.08 (0.72-1.51) * 0.92 (0.52-1.24) * 
Bilirubin (mg/dL) 0.62 ± 0.25  0.61 ± 0.23 0.62 ± 0.24 
* p<0.05, vs controls; § p<0.05 vs responders.  
Hb: haemoglobin concentration; RBC: red blood cell count; MCV: mean cell volume; MCH: mean cell haemoglobin; MCHC: mean cell haemoglobin concentration; RDW: red 
blood cell distribution width; RPI: reticulocyte production indice. Results are presented as mean ± standard deviation or as median (interquartile ranges). 
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 We found similar statistical differences between groups 
when CKD patients with diabetic nephropathy were removed 
from the analyses, to exclude diabetes as a confounding fac-
tor (as previously referred). Actually, the values that we 
found for CKD patients, with and without diabetic nephropa-
thy, were very similar. 
DISCUSSION 
 The treatment of anaemia, the most frequent haematolo- 
gical alteration found in CKD patients, has been improved in 
the last years by rhEPO therapy. This therapy increases RBC 
production, providing an increased number of younger and 
more powerful RBCs in terms of functionality. However, it 
is known that in this kind of patients RBCs have to circulate 
in an adverse plasma environment and that they have to un- 
dergo a haemodialysis procedure regularly. Both conditions 
may induce metabolical and/or physical RBC damage that 
may lead to premature senescence and removal of RBCs.  
 As previously described [1-3], in the present study, de-
spite rhEPO therapy, anaemia was a common finding in our 
CKD patients under haemodialysis (Table 1). The reduction 
in Hb concentration was associated with a statistically sig-
nificant increase in circulating reticulocytes and RPI (twice 
the value of controls), reflecting the erythropoietic stimulus 
triggered by rhEPO therapy. The higher RDW observed in 
CKD patients, may reflect the rise in reticulocyte count 
and/or a higher RBC damage, with anisocytosis develop-
ment.  
 To evaluate oxidative and proteolytic RBC damage we 
evaluated the band 3 profile and MBH. As Hb denatures, it 
binds to intracellular surface of the membrane, leading to 
band 3 aggregation [31]. Previous studies in our lab showed 
that oxidative stress conditions [16-20] are associated to an 
increase in band 3 HMWAg and a reduction in Pfrag. 
Moreover, we have also reported that younger RBCs present 
a decreased band 3 HMWAg and a rise in Pfrag [17].  
 We report, for the first time, changes in the erythrocyte 
membrane band 3 profile in CKD patients. CKD patients 
presented a decrease in HMWAg and in HMWAg/band 3 
monomer ratio. These changes seem to reflect a younger 
RBC population. In fact, erythrocyte membranes from 
younger RBCs are poorer in HMWAg and richer in Pfrag. 
However, our CKD also presented a decrease in Pfrag and in 
Pfrag/band 3 monomer ratio, which are associated to a rise in 
RBC damage. Thus, it seems that the band 3 profile observed 
in CKD patients is associated both to an increase in younger 
RBCs and to an increase in damaged RBCs. The same 
results were previously described to be associated with 
pregnancy [20]. 
 Haemodialysis patients exhibited higher plasma levels of 
TBA and also of TAS. A higher TBA/TAS ratio reflecting a 
higher rise in TBA than in TAS, is in favour of an oxidative 
stress. No difference between controls and CKD patients was 
found for RBC SOD activity; this, has been related to an 
enzymatic inactivation due to hyperproduction of ROS [32]; 
the increase in RBC GPx activity is probably due to the 
higher levels of circulating reticulocytes (almost twice the 
value of controls). Actually, it has been reported that 
reticulocytes present a higher GPx activity when compared 
to mature RBCs. Data of about antioxidant RBC enzymes 
activities in haemodialysis patients are controversial, as 
authors reported decreased, increased or even unchanged 
enzyme activities [33-35].  
Table 2.  RBC Damage, Enzymatic Activities of Erythrocyte SOD and GPx, Plasma Lipid Peroxidation, Antioxidant Status and 
CRP, for Controls and CKD Patients 
 Controls 
(n=26) 
Responders 
(n=32) 
Non-Responders 
(n=31) 
HMWAg (%) 19.90 (15.42-21.12) 14.86 (11.30-20.19) * 15.92 (14.28-18.68) * 
Band 3 monomer (%) 55.28 (53.39-57.41) 61.26 (56.08-65.06) * 62.17 (58.01-64.29) * 
Pfrag (%) 26.29 ± 4.78 24.01 ± 6.03 21.34 ± 5.78 * § 
HMWAg/ Band 3 monomer 0.33 ± 0.07 0.26 ± 0.09 * 0.27 ± 0.06 * 
Pfrag/ Band 3 monomer 0.48 ± 0.11 0.41 ± 0.14 * 0.35 ± 0.13 * § 
MBH (x10-4 %) 53.00 (37.75-89.75) 45.50 (25.25-80.75) 58.50 (30.50-100.75) 
GPx (IU/g Hb) 35.62 ± 8.83  48.73±13.46 * 43.11±13.87 
SOD (IU/g Hb) 1039.8 (737.4-1331.6) 858.97 (662.4-1256.5) 1074.76 (581.6-2638.7) 
TBA (x10-3 mmol/L) 0.84 ± 0.27 1.49 ± 0.32 * 1.48 ± 0.30 * 
TAS (mmol/L) 1.41 ± 0.29 1.81 ± 0.24 * 1.76 ± 0.24 * 
TBA/TAS 0.60 ± 0.28 0.83 ± 0.18 * 0.86 ± 0.18 * 
CRP (mg/dL) 1.75 (0.76-4.70) 3.20 (1.73-7.23) * 10.14 (3.82-38.99) * § 
* p<0.05, vs controls; § p<0.05 vs responders.  
HMWAg; high molecular weight aggregates; Pfrag: proteolytic fragments; SOD: superoxide dismutase; GPx: glutathione peroxidase; MBH: membrane bound haemoglobin; TAS: 
total antioxidant status; TBA: plasma lipid peroxidation; CRP: C-reactive protein. 
Results are presented as mean ± standard deviation or as median (interquartile ranges). 
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 The increased erythropoietic stimulation triggered by 
rhEPO therapy, seems to provide a younger RBC population 
that has to face an adverse plasma oxidative environment as 
shown by higher values of plasma lipid peroxidation and by 
the band 3 profile showing changes denoting a younger but 
also a damaged RBC population.  
 Analyzing the haematological results presented by the 
two groups of CKD patients, responders and non-responders 
to rhEPO therapy, we found that the non-responders pre-
sented anaemia, showing a statistically significant decrease 
in Hb, Ht and RBC count (Table 1). These changes were 
associated to significantly lower MCH and MCHC values, 
showing a hypocromic RBC change, which was not due to 
erythropoietic deficiencies in iron, folic acid or vitamin B12 
(data not shown). A statistically significant rise in RDW was 
also observed in non-responders that could reflect reticulocy-
tosis and/or anisocytosis due to a higher RBC damage. As 
responders and non-responders presented with a similar re-
ticulocyte value, though presenting non-responders a trend to 
higher reticulocyte count, the increase in RDW seems to 
mainly result from anisocytosis, reflecting a higher RBC 
damage.  
 Non-responders CKD patients, compared to responders, 
though presenting a similar reticulocyte and RBC count, 
showed a decrease in Pfrag and in Pfrag/band 3 monomer 
ratio, and a trend to higher values of MBH (Table 2), sug-
gesting that they present a higher RBC damage that may 
result from a more adverse plasma microenvironment. Resis-
tance to rhEPO therapy in CKD patients seems, therefore, to 
be associated to an increase in RBC damage. No alterations 
were found in non-responders patients in the parameter re-
lated to RBC antioxidant capacity; TAS and TBA.  
 This study also shows that the haemodialysis procedure 
per se does not lead to an increase in the studied markers 
RBC damage. Actually, no differences were found after 
haemodialysis, in band 3 profile and, besides that, a decrease 
in MBH, TBA and TAS were observed, probably reflecting 
the improvement in the plasma environment and/or the re-
moval of damaged RBCs.  
 It is known that the linkage of denatured Hb to RBC 
membrane at the cytoplasmic pole of the protein band 3 fa-
vours the aggregation of this transmembrane protein [36] and 
turns the cell membrane more rigid. In our study, the MBH 
decreased after the haemodialysis procedure, suggesting that 
damaged RBCs may have been removed from circulation. 
Actually, damaged RBCs may be more susceptible to 
haemolyse, when submitted to mechanical stress as may oc-
cur during haemodialysis. Another possibility is that the 
small portions of membrane with bound Hb and band 3 ag-
gregates might be lost by a process of membrane vesicula-
tion, as occurs in splenic sinusoids, where RBCs have also to 
deform, to go through that microvasculature.  
 The increased indicators of RBC damage found in our 
CKD patients, particularly in non-responders (decrease in 
Pfrag and a trend to increase of MBH), was also associated 
to an increase in CRP. There are evidences that a rise in 
proinflammatory cytokines levels (especially interleukine-6) 
and in the acute phase reactant CRP, are among the most 
powerful independent predictors of resistance to rhEPO ther-
apy, and are associated with cardiovascular morbidity and 
mortality in CKD patients [4-7]. There are also some evi-
dence of a bidirectional and synergistic linkage between in-
flammation and oxidative stress. However, further studies 
are required targeting specific oxidative pathways, as well as 
specific inflammatory pathways to elucidate this biological 
linkage [6,7]. The increase RBC damage found in CKD pa-
tients, particularly in non-responders, can also be associated 
to the proteolytic effect of elastase released from neutrophils 
during haemodialysis procedure. In fact, recently higher 
plasma levels of elastase were demonstrated by us in non-
responders patients [37]. 
 Our data suggest that CKD patient’s present younger 
RBC population, which could be related to the rhEPO ther-
apy. The adverse plasma environment associated to CKD 
patients under hemodialysis imposes changes in band 3 pro-
file, particularly in non-responders. 
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